Evidence map›Paper›PMID 39546024›Full record

ArticleActa neuropathologica2024

Microglia contribute to the production of the amyloidogenic ABri peptide in familial British dementia.

Charles Arber, Jackie M Casey, Samuel Crawford, Naiomi Rambarack, Umran Yaman, Sarah Wiethoff, Emma Augustin, Thomas M Piers, Matthew Price, Agueda Rostagno and 10 more

Abstract read
In one paragraph

Article in Acta neuropathologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Charles ArberDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
Jackie M CaseyDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
Samuel CrawfordDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
Naiomi RambarackDementia Research Institute at UCL, London, UK.
Umran YamanDementia Research Institute at UCL, London, UK.
Sarah WiethoffKlinik für Neurologie mit Institut für Translationale Neurologie Albert Schweitzer Campus, Gebäude A1, 48149, Münster, Germany.
Emma AugustinDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
Thomas M PiersDepartment of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK.
Matthew PriceDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
Agueda RostagnoDepartment of Pathology, New York University Grossman School of Medicine, New York, USA.
Jorge GhisoDepartment of Pathology, New York University Grossman School of Medicine, New York, USA.
Patrick A LewisDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
Tamas ReveszThe Queen Square Brain Bank for Neurological Disorders, Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, London, UK.
John HardyDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
Jennifer M PocockDepartment of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK.
Henry HouldenDepartment of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, London, UK.
Jonathan M SchottDementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.
Dervis A SalihDementia Research Institute at UCL, London, UK.
Tammaryn LashleyDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK. t.lashley@ucl.ac.uk.
Selina WrayDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK. selina.wray@ucl.ac.uk.

Funding

Relevance of Abeta N-terminal Truncations for Alzheimer Pathogenesis and Therapy - Resubmission - 1RF1AG059695 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GHISO, JORGE A · 2019 to 2019
$3.7M
Alzheimer's Research UK ARUK-SRF2016B-2Alzheimer's Society AS-JF-18-008EPA EP-C-18-008Medical Research Council MR/M02492X/1NIA NIH HHS RF1 AG059695NIH HHS RF1 AG059695
6 · The paper itself

Abstract

Mutations in ITM2B cause familial British, Danish, Chinese, and Korean dementias. In familial British dementia (FBD), a mutation in the stop codon of the ITM2B gene (also known as BRI2) causes a C-terminal cleavage fragment of the ITM2B/BRI2 protein to be extended by 11 amino acids. This fragment, termed amyloid-Bri (ABri), is highly insoluble and forms extracellular plaques in the brain. ABri plaques are accompanied by tau pathology, neuronal cell death and progressive dementia, with striking parallels to the aetiology and pathogenesis of Alzheimer's disease. The molecular mechanisms underpinning FBD are ill-defined. Using patient-derived induced pluripotent stem cells, we show that expression of ITM2B/BRI2 is 34-fold higher in microglia than neurons and 15-fold higher in microglia compared with astrocytes. This cell-specific enrichment is supported by expression data from both mouse and human brain tissue. ITM2B/BRI2 protein levels are higher in iPSC-microglia compared with neurons and astrocytes. The ABri peptide was detected in patient iPSC-derived microglial lysates and conditioned media but was undetectable in patient-derived neurons and control microglia. The pathological examination of post-mortem tissue supports the presence of ABri in microglia that are in proximity to pre-amyloid deposits. Finally, gene co-expression analysis supports a role for ITM2B/BRI2 in disease-associated microglial responses. These data demonstrate that microglia are major contributors to the production of amyloid forming peptides in FBD, potentially acting as instigators of neurodegeneration. Additionally, these data also suggest ITM2B/BRI2 may be part of a microglial response to disease, motivating further investigations of its role in microglial activation. These data have implications for our understanding of the role of microglia and the innate immune response in the pathogenesis of FBD and other neurodegenerative dementias including Alzheimer's disease.

Indexed as

DementiaInduced Pluripotent Stem CellsMicrogliaAdaptor Proteins, Signal TransducingAmyloid beta-PeptidesAnimalsBrainHumansMiceNeuronsAdaptor Proteins, Signal TransducingAmyloid beta-PeptidesITM2B protein, humanAlzheimer’s diseaseAmyloidDementiaFamilial British dementiaiPSCMicroglia

Identifiers

PMID39546024
PMCPMC11568029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.